Compare HQL & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HQL | CTKB |
|---|---|---|
| Founded | 1992 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 510.2M | 433.8M |
| IPO Year | N/A | 2021 |
| Metric | HQL | CTKB |
|---|---|---|
| Price | $17.19 | $5.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.88 |
| AVG Volume (30 Days) | 120.9K | ★ 1.9M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | N/A | ★ $196,828,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.62 |
| P/E Ratio | $17.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.34 | $2.37 |
| 52 Week High | $14.37 | $7.30 |
| Indicator | HQL | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 53.94 |
| Support Level | $16.86 | $5.15 |
| Resistance Level | $17.70 | $5.50 |
| Average True Range (ATR) | 0.39 | 0.43 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 62.22 | 33.33 |
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.